International Journal of Physics
ISSN (Print): 2333-4568 ISSN (Online): 2333-4576 Website: http://www.sciepub.com/journal/ijp Editor-in-chief: B.D. Indu
Open Access
Journal Browser
Go
International Journal of Physics. 2016, 4(3), 69-73
DOI: 10.12691/ijp-4-3-5
Open AccessArticle

A 5 Year Retrospective Study of 131I Therapy for Thyroid Cancer Practice in King Abdulaziz University Hospital

Mawya A. Khafaji1 and Majdi R. ALnowaimi2,

1Department of Radiology, Faculty of Medicine Kind Abdulaziz University, Jeddah, Saudi Arabia

2Department of Nuclear engineering, faculty of Engineering Kind Abdulaziz University, Jeddah, Saudi Arabia

Pub. Date: May 11, 2016

Cite this paper:
Mawya A. Khafaji and Majdi R. ALnowaimi. A 5 Year Retrospective Study of 131I Therapy for Thyroid Cancer Practice in King Abdulaziz University Hospital. International Journal of Physics. 2016; 4(3):69-73. doi: 10.12691/ijp-4-3-5

Abstract

Since 1940s, intake of Iodine 131 is a deeprooted postoperative therapy for malignant thyroid. However, clinical practice does differ significantly between hospitals. This paper presents a retrospective study of a clinical practice for patients diagnosed with thyroid cancer at King Abdulaziz University Hospital (KAUH). The aim of this study was to benchmark KAUH practice patterns against international guidelines. A total of 100 patients with thyroid cancer were included, 70% females and 30% males with median age of 42.5 and 43.5 years respectively. Cases were patients, diagnosed with thyroid cancer and treated with radioactive iodine at KAUH in Saudi Arabia between 2005 and 2011. Some additional patient’s data were excluded from the study because of missing information or lost to follow-up. Medical records included patient’s gender, age, clinical diagnoses, iodine dose, and the recurrence. Where, thirty-three percent (33%) of the patients had papillary carcinoma, (3%) had follicular carcinoma and (1%) had Hurtle cell tumors. All patients had their total/partial thyroidectomy at KAUH. Dose administered ranged from (50 to 300) mCi with the 61% receiving a dose of 100mCi. A statistical test, Chisquare test, were used to allow us to test for deviations of observed frequencies from expected frequencies. The medical record showed that 3% of the patient had died and 4% had a recurrence that was successfully treated by the time of the study. Moreover, the 5-year survival rates for patients with thyroid cancers was 93%. The thyroid cancer incidence and the I-131 practice in KAUH is consistent with international data and standards.

Keywords:
radioactive iodine thyroid cancer nuclear medicine

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, BalonHR. (2002). Procedure guideline for therapy of thyroid disease with (131)iodine. Journal of Nuclear Medicine.43(6):851-61
 
[2]  Kingdom of Saudi Arabia Ministry of Health National Cancer Registry. Cancer incidence and survival report Saudi Arabia (2007). Available at: http://www.scr.org.sa/reports/SCR2007.pdf.
 
[3]  Parthasarathy, KL, Crawford ES. (2002). Treatment of Thyroid Carcinoma: Emphasis on High-Dose 131I Outpatient Therapy. Journal of Nuclear Medicine Technology.30(4):165-71.
 
[4]  Pacini F, Castanga MG, Brilli L, Pentheroudakis G. (2010). Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 21(5): v214-19.
 
[5]  Hoelzer S, Steiner D, Bauer R, Reiners C, Farahati J, Hundahl SA, Dudeck J. (2000). Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Europian Journal of Nuclear Medicine. 27(10):1465-72.
 
[6]  Seidlin SM, Oshry E, Yalow AA 1948 Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma; a preliminary report. TheJournal of Clinical Endocrinology & Metabolism.8:423-432.
 
[7]  Nostrand, DV, Wartofsky L. (2007). Radioiodine in the Treatment of Thyroid Cancer.Endocrinology and Metabolism Clinics of North America.36(3):807-22.
 
[8]  Dorn R, Kopp J, Vogt H, Heidenreich P, Caroll RG, Gulec SA. (2003). Dosimetry-Guided Radioactive Iodine Treatment in Patients with Metastatic Differentiated Thyroid Cancer: Largest Safe Dose Using a Risk-Adapted Approach. The Journal of Nuclear Medicine. 44(3): 451-56.
 
[9]  Carballo M, Quiros RM. (2012). Review Article: To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients. Journal of Oncology.(2012):1-11.
 
[10]  Valachis A, Nearchou A. (2012).High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis. ActaOncologica. 0(0):1-8.
 
[11]  Ogbera, AO. (2010). A two-year audit of thyroid disorders in an urban hospital in Nigeria.Nigerian Quarterly Journal of Hospital Medicine. 20(2): 81-5.
 
[12]  Abdullah M. (2002). Thyroid cancer: The Kuala Lumpur experience. The New Zealand Journal of Surgery.72(9):660-4.
 
[13]  Gkountouvas A, Nikas M, Chatjimarkou F, Thomas D, Georgiadis P, Kaldrimidis P. (2010). Thyroid cancer in Greece.A tertiary center experience. Journal of Balkan Union of Oncology. 15(4):674-8.
 
[14]  Shields JA, Farringer JL Jr. (1977). Thyroid cancer. Twenty-three years' experience at Baptist and St. Thomas Hospitals. The American Journal of Surgery. 133(2): 211-5.
 
[15]  Hsieh SH, Chen ST, Hsueh C, Chao TC, Lin JD. (2012). Gender- Specific Variation in the prognosis of papillary thyroid cancer TNM stages II to IV. International Journal of Endocrinology. 2012 (2012): Article ID 379097, 5 pages.
 
[16]  Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI; National Thyroid Cancer Treatment Cooperative Study Group. (2012). The impact of age and gender on papillary thyroid cancer survival. The Journal of Clinical Endocrinology & Metabolism. 97(6):E878-87.
 
[17]  Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM. (2012). American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 22(11); 1104-1139.
 
[18]  Haymart DG, Stewart AK, Griggs JJ, Banerjee M. (2013). Disease Severity and Radioactive Iodine Use for Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 98(2): 678-686.
 
[19]  Grünwald F, Ruhlmann J, Ammari B, Knopp R, Hotze A, Biersack HJ. (1988). Experience with a high-dose therapy concept in metastatic differentiated thyroid cancer. Nuklearmedizin. 27(6):266-71.
 
[20]  Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, Pochart JM, Cochet I, Crevisy E, Dalac A, Papathanassiou D, Toubeau M. (2012). Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.The Journal of Clinical Endocrinology & Metabolism. 97(5): 1526-35.
 
[21]  Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. (2010). The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 20(11):1235-45.
 
[22]  Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DD, Daniels GH. (2012). Lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid cancer: long-term follow-up. Thyroid. 22(4):369-76.
 
[23]  Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I. (2012). Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?.Surgery. 152(6):1096-105.
 
[24]  Afroz S, Ahmed K, Yasmeen S, Ahmed F, Nisa L. (1992). Role of radioiodine in management of thyroid cancer: experience with 70 cases. Bangladesh Medical Research Council Bulletin. 18(2): 68-71.
 
[25]  Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini E, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. (2009). Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 19(11); 1167-1214.
 
[26]  Clerc J. Bienvenu-perrard M. Pichard de Malleray C. Dagousset F. Delbot T. Dreyfuss M. Groussin L. Marlowe RJ, Leger FA. Chevalier A. (2012) Outpatient thyroid remnant ablation using repeated low I131 iodine activites (740 MBq/20mCi * 2) in patients with low-risk differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 97:871-80
 
[27]  Van Nostrand D, Atkins F. (2011).Pediatric Differentiated Thyroid Cancer: Can the Prescribed Activity of I-131 Be Increased? The Journal of Clinical Endocrinology & Metabolism. 96(8):2401-2403
 
[28]  Morris LGT, Sikora AG, Tosteson TD, Davies L. (2013). The Increasing Incidence of Thyroid Cancer: The Influence of Access to Care. Thyroid. 23(7); 885-891.